Status:
COMPLETED
Mass Screening and Treatment for Reduction of Falciparum Malaria
Lead Sponsor:
University of Oxford
Conditions:
Plasmodium Falciparum Malaria
Eligibility:
All Genders
1+ years
Phase:
NA
Brief Summary
In this project, the investigators aim at an operational research deployment of Ultrasensitive Rapid Diagnostic Test (URDT) -based Mass Screening and Treatment (MSAT) in the Malaria Elimination Task F...
Detailed Description
STUDY DESIGN Stepped-wedge open-label, non-randomized, cluster intervention. This study will be performed in clusters (hamlet (isolated group of household, village, or group of village). The interve...
Eligibility Criteria
Inclusion
- All persons living in the village or cluster of villages will be eligible for MSAT intervention.
- Individuals living in smaller settlements (permanent or temporary) within walking distance of a selected intervention village will also be eligible.
- Large "work-related" settlements in the vicinity of a targeted village (military camps, logging camp, mining site) will be approached by the team to be included in the screening and treatment activity. They will be included in the analysis as a unit within a cluster of villages if all the study information can be collected (including follow-up survey for Group 1).
Exclusion
- Individuals who do not provide informed consent for both URDT screening and treatment in case of positive result. Individuals will be given the possibility to refuse the collection of the 200µL reference sample or the DBS collection but participate to URDT screening and treatment.
- Children \<1 year old
- Individuals with a documented Pf-positive malaria RDT who received treatment (AL+sld PMQ) during the previous 7 days.
- NB: Individuals who were diagnosed infected with PF and received a treatment between 7 and 30 days before the intervention are still likely to be URDT positive due to the persistence of HRP2, and this will result in treatment of individuals who are likely uninfected. However, in a high prevalence area or in an outbreak context, previous infection signals exposure, and DP will provide a protection against a likely re-infection.
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
5542 Patients enrolled
Trial Details
Trial ID
NCT04093765
Start Date
November 1 2018
End Date
December 31 2020
Last Update
March 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shoklo Malaria Research Unit
Mae Sot, Changwat Tak, Thailand, 63110